bullish
Sinopharm Group (1099 HK): Stable Pharma Distribution Business Despite Weak Demand for Vaccine
293 Views12 Jan 2022 17:36
SUMMARY
- With its nationwide distribution and delivery network, Sinopharm Group Co Ltd H (1099 HK) remains a beneficiary of increasing adoption of China’s VBP scheme for drug procurement.
- Despite decreasing demand for Sinopharm’s COVID-19 vaccine, its pharmaceutical distribution business is expected to remain stable, driven by the steady recovery in China’s healthcare industry.
- The company is successfully promoting fast-growing oncology products. Its strategic partnership with I-Mab (IMAB US) further strengthens competitive edge, as I-Mab has a robust pipeline for China market.
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Rising
Tina Banerjee
Global Healthcare Analyst
- Pre-IPO YSB Inc (YSB.HK) - The Business Model Is Facing Challenges26 Apr 2023
- Sinopharm Group (1099 HK): Strong 2022 Results; Double-Digit Top and Bottom-Line Growth to Continue06 Apr 2023
- Sinopharm Group (1099 HK): Industry Tailwind and China Reopening To Drive Growth29 Dec 2022
- Sinopharm Group (1099 HK): Stable Pharma Distribution Business Despite Weak Demand for Vaccine12 Jan 2022
x